Coordinated C-suite selling, especially in the absence of recent buying, may signal lack of confidence in near-term prospects. Traders should monitor upcoming earnings, pipeline updates, or potential financing activity that could dilute shares.
VERA drugs
VERA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $42.06entry
- T+1 · 9mo ago +0.74%α +0.00% · $42.37
- T+5 · 9mo ago −3.90%α −4.52% · $40.42
- T+20 · 8mo ago −3.16%α +0.78% · $40.73
- T+60 · 6mo ago −18.33%α −26.58% · $34.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three senior executives at Vera Therapeutics, the Chief Regulatory Officer, Chief Operating Officer, and Chief Commercial Officer, collectively sold over $266,000 worth of shares in a coordinated open-market transaction on February 23, 2026. All trades occurred at the same price, indicating a planned selling event, though no material non-public information is indicated by the timing.
Key Financial Metrics
Key Facts
- Three C-suite executives sold shares simultaneously on February 23, 2026.
- Total value of sales: $266,513.79 across 6,348 shares.
- All transactions were open-market sales (Form 4 'S' codes) at identical price: $41.9839 per share.
- Sellers include Chief Commercial Officer, Chief Operating Officer, and Chief Regulatory Officer, all key operational leaders.
Financial Impact
$266,514 in insider selling over one day
Risk Factors
- Potential perception of insider pessimism ahead of a catalyst or earnings release.
- Possible upcoming stock offering or financing that insiders are preemptively hedging against.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-VERA-1772067485262 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers